NCT04203472View on ClinicalTrials.gov

Optimal Type of Inhaler in Cough Variant- or Cough Predominant Asthma

NACompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

January 20, 2019

Primary Completion Date

February 28, 2022

Study Completion Date

March 30, 2022

Conditions
AsthmaCough Variant Asthma
Interventions
DEVICE

Budesonid or budesonide/fomoterol administered by DPI

Miflonide Breezhaler 200 mcg or Oxodil Aerolizer 12 mcg

DEVICE

Budesonid or budesonide/fomoterol administered by MDI

Budiair 200 mcg or Atimos 12 mcg

Trial Locations (1)

02-097

Department of Internal Medicine, Pneumonology and Allergology, Medical University of Warsaw, Warsaw

All Listed Sponsors
lead

Medical University of Warsaw

OTHER

NCT04203472 - Optimal Type of Inhaler in Cough Variant- or Cough Predominant Asthma | Biotech Hunter | Biotech Hunter